Skip to content
Tablet Allopathic

Capmaxen 200 mg tablet

Generic: Capmatinib Hydrochloride

Company: Everest Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength200 mg
PackStrip: 42000.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated May 2, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Capmatinib Hydrochloride 200 mg tablets

Prices as listed on BestinMeds.

1 brand listed
Capmaxen (this medicine)1500.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Capmatinib Hydrochloride guide

Indications

Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA approved test.

Dosage and administration

Patient Selection: Select patients for treatment with Capmatinib based on the presence of a mutation that leads to MET exon 14 skipping in tumor or plasma specimens. If a mutation that leads to MET exon 14 skipping is not detected in a plasma specimen, test tumor tissue if feasible. Recommended Dose: The recommended dosage of Capmatinib is 400 mg orally twice daily with or without food. Swallow Capmatinib tablets whole. Do not break, crush or chew the tablets. If a patient misses or vomits a dose, instruct the patient not to make up the dose, but to take the next dose at its scheduled time.

Side effects

Lung or breathing problems Liver problems. Pancreas problems. Swelling of your hands or feet Nausea Muscle or bone pain Tiredness and weakness Vomiting Trouble breathing Cough Loss of appetite Changes in certain blood tests

Precautions and warnings

Interstitial Lung Disease (ILD): Immediately withhold Capmatinib in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified. Hepatotoxicity: Monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of Capmatinib, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Based on the severity of the adverse reaction, withhold, dose reduce, or permanently discontinue Capmatinib. Pancreatic Toxicity: Monitor amylase and lipase at baseline and regularly during treatment with Capmatinib. Based on the severity of the adverse drug reaction, temporarily withhold, dose reduce, or permanently discontinue Capmatinib. Risk of Photosensitivity: Advise patients to limit direct ultraviolet exposure during treatment with Capmatinib. Embryo-Fetal Toxicity: Based on findings from animal studies and its mechanism of action, Capmatinib can cause fetal harm when administered to a pregnant woman.

Pregnancy and lactation

Pregnancy: Capmatinib can cause fetal harm when administered to a pregnant woman. There are no available data on Capmatinib use in pregnant women. Advise pregnant women of the potential risk to a fetus. Lactation: Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Capmatinib and for 1 week after the last dose. Females and Males of Reproductive Potential: Based on animal data, Capmatinib can cause malformations at doses less than the human exposure based on AUC at the 400 mg twice daily clinical dose. Pregnancy Testing: Verify pregnancy status for females of reproductive potential prior to starting treatment with Capmatinib. Contraception- Females: Advise females of reproductive potential to use effective contraception during treatment with Capmatinib and for 1 week after the last dose. Males: Advise males with female partners of reproductive potential to use effective contraception during treatment with Capmatinib and for 1 week after the last dose

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250